Candel Therapeutics' CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial

By Proactive Investors / October 02, 2025 / www.youtube.com / Article Link


Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to highlight new subgroup analyses from the ...

Recent News

Bank of Japan boosts rates, continuing an unwinding carry trade

December 22, 2025 / www.canadianminingreport.com

Gold stocks outperform equity market slide

December 22, 2025 / www.canadianminingreport.com

Silver inventories rebound in UK, output from major producers rises

December 15, 2025 / www.canadianminingreport.com

Silver's three-month outperformance continues

December 15, 2025 / www.canadianminingreport.com

Silver & Copper Supply Distortions Continue

December 08, 2025 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok